PFA herewith Annual Secretarial Compliance Report for the year 31st March 2025 pursuant to Regulation 24A 0f SEBI LODR Regulations.
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ajanta Pharma has submitted its Annual Secretarial Compliance Report for the financial year ended 31st March 2025, as required under Regulation 24A of SEBI LODR rules. The report, prepared by M/s. Alwyn D'Souza & Co., confirms overall compliance with SEBI regulations, listing rules, insider trading norms, related party transaction disclosures, and secretarial standards. One minor observation was noted: a delay in uploading Q4 FY24 financial results on NSE's NEAPS system (uploaded at 4:38 PM instead of within 30 minutes of the 4:00 PM board meeting conclusion on 2nd May 2024), attributed to technical issues. BSE upload was completed at 4:30 PM, and no penalty was levied by NSE. No actions were taken by SEBI or stock exchanges against the company during the review period.
This is a routine regulatory filing with no material adverse findings. The single minor technical delay had no financial penalty and is unlikely to affect shareholder value or stock price. Overall compliance status remains clean.